U.S. markets closed

Frequency Therapeutics, Inc. (FREQ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.52+0.01 (+0.13%)
At close: 4:00PM EDT
7.52 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close7.51
Open7.52
Bid7.45 x 800
Ask7.60 x 2200
Day's Range7.29 - 7.70
52 Week Range6.65 - 58.37
Volume140,273
Avg. Volume263,992
Market Cap258.816M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.58
Earnings DateNov 15, 2021 - Nov 19, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Frequency Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/05/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • Benzinga

    Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors

    Frequency Therapeutics Inc (NASDAQ: FREQ) has announced that four additional sensorineural hearing loss (SNHL) subjects from its FX-322-111 open-label study achieved statistically significant hearing improvements. The patients were evaluated 8 to 12 months following initial dosing. Including the five initial responders, a total of nine subjects in the study (n=32) have shown statistically significant improvements in word recognition scores, a key measure of speech perception, at time points betw

  • Business Wire

    Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points

    LEXINGTON, Mass., September 22, 2021--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore human function, today announced that four additional sensorineural hearing loss (SNHL) subjects from its FX-322-111 open-label study achieved statistically significant hearing improvements when evaluated 8 to 12 months following initial dosing.

  • Business Wire

    Frequency Therapeutics to Present at Upcoming Investor Conferences

    LEXINGTON, Mass., September 08, 2021--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present at the following investor conferences: